LEQEMBI is a prescription medicine used to treat people with early Alzheimer’s disease, which includes mild cognitive impairment (MCI) or mild dementia stage of disease.

Nov 20, 2025 · What is Leqembi? Leqembi (lecanemab) is a monoclonal antibody used for Alzheimer’s disease to help slow the decline in memory, thinking, and behavior in patients who have mild …

Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of Alzheimer's disease. [2][6] Lecanemab is an amyloid beta -directed antibody. [2]

Leqembi (lecanemab) is a new type of medicine that can slow down how quickly Alzheimer’s disease gets worse. Leqembi is a treatment for people who are in the early stages of Alzheimer’s disease,...

Nov 25, 2025 · Learn about side effects, uses, cost, and more for Leqembi (lecanemab-irmb), a prescription drug that treats Alzheimer’s disease in adults.

Lecanemab (Leqembi®) is an antibody intravenous (IV) infusion therapy that targets and removes beta-amyloid from the brain. It has received traditional approval from the U.S. Food and Drug …

4 days ago · The inclusion of LEQEMBI in this list marks a meaningful step toward expanding access to early Alzheimer’s Disease (AD) treatment in China. The Commercial Insurance Innovative Drug List …

Mar 31, 2025 · Leqembi is the product of two decades of research into making an antibody that attacks amyloid deposits and stimulates microglia —immune cells that care for neurons— to clean up the …

Find initiation and maintenance dosing info for LEQEMBI® (lecanemab-irmb), including IV and at-home subcutaneous auto-injector options. See safety & Boxed WARNING on amyloid-related imaging …

Stockholm, Sweden, December 4, 2025 – BioArctic AB’s (publ) (Nasdaq Stockholm: BIOA B) partner Eisai presented the latest findings on time saved with continued treatment with lecanemab …